Eledon Pharmaceuticals (ELDN) has agreed to collaborate with Sernova Biotherapeutics to evaluate tegoprubart in patients with type 1 diabetes, Sernova said Wednesday.
Under the agreement, Eledon will supply tegoprubart to replace tacrolimus in Cohort C of Sernova's phase 1/2 cell pouch bio-hybrid organ trial in patients with type 1 diabetes, according to a statement.
Shares of Eledon were up 7% in recent premarket activity Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.